SUMMIT THERAPEU/S (NASDAQ:SMMT) has received an average recommendation of “Hold” from the nine research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $3.00.
A number of equities analysts have issued reports on the company. Zacks Investment Research raised SUMMIT THERAPEU/S from a “strong sell” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Tuesday, February 5th. HC Wainwright reaffirmed a “buy” rating on shares of SUMMIT THERAPEU/S in a research report on Tuesday, February 19th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of SUMMIT THERAPEU/S in a research report on Thursday, February 14th.
SUMMIT THERAPEU/S stock traded down $0.03 during midday trading on Friday, hitting $1.59. 29,809 shares of the company were exchanged, compared to its average volume of 53,312. The firm has a market capitalization of $22.01 million, a PE ratio of 1.89 and a beta of 1.42. SUMMIT THERAPEU/S has a fifty-two week low of $1.10 and a fifty-two week high of $13.76.
SUMMIT THERAPEU/S (NASDAQ:SMMT) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.13). The company had revenue of $0.66 million for the quarter, compared to analyst estimates of $4.44 million. SUMMIT THERAPEU/S had a return on equity of 29.15% and a net margin of 17.27%. On average, sell-side analysts anticipate that SUMMIT THERAPEU/S will post -1.23 earnings per share for the current year.
A hedge fund recently raised its stake in SUMMIT THERAPEU/S stock. Renaissance Technologies LLC boosted its position in SUMMIT THERAPEU/S (NASDAQ:SMMT) by 55.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 76,330 shares of the company’s stock after acquiring an additional 27,230 shares during the quarter. Renaissance Technologies LLC owned 0.55% of SUMMIT THERAPEU/S worth $140,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 21.93% of the company’s stock.
About SUMMIT THERAPEU/S
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Recommended Story: How to trade on quiet period expirations
Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with MarketBeat.com's FREE daily email newsletter.